Abstract Phenylalanine hydroxylase (PAH) is a non-heme iron enzyme that catalyzes oxidation of phenylalanine to tyrosine, a reaction that must be kept under tight regulatory control. Mammalian PAH has a regulatory domain in which binding of the substrate leads to allosteric activation of the enzyme. However, the existence of PAH regulation in evolutionarily distant organisms, for example some bacteria in which it occurs, has so far been underappreciated. In an attempt to crystallographically characterize substrate binding by PAH from Chromobacterium violaceum, a single-domain monomeric enzyme, electron density for phenylalanine was observed at a distal site 15.7 Å from the active site. Isothermal titration calorimetry (ITC) experiments revealed a dissociation constant of 24 ± 1
Introduction
Phenylalanine hydroxylase (PAH) is a non-heme iron (II) enzyme that, in the presence of oxygen and cofactor 6(R)-L-erythro-tetrahydrobiopterin (BH 4 ), catalyzes hydroxylation of L-phenylalanine to L-tyrosine (Fitzpatrick 2003; Kappock and Cardonna 1996) . Phenylketonuria (PKU) occurs when dysfunctional PAH in humans impairs metabolism of phenylalanine, leading to accumulation of abnormal levels of phenylalanine in the blood (Erlandsen et al. 2003; Scriver 1995) . In mammals, PAH is a homotetramer-each subunit comprises three distinct domains, an N-terminal regulatory domain, a catalytic domain, and a C-terminal oligomerization domain Flatmark and Stevens 1999) . Because conversion of phenylalanine to tyrosine is essentially irreversible and because PAH is expressed abundantly in the liver, activity of the enzyme is tightly regulated via allosteric activation by its own substrate, phenylalanine, binding at a secondary site in the regulatory domain (Chehin et al. 1998; Kaufman 1993; Kobe et al. 1999; Li et al. 2011) . Sequence homology analysis comparing the N-terminal regulatory domains of eukaryotic PAHs and prephenate dehydratase, an enzyme required for phenylalanine biosynthesis in bacteria, led to the discovery of two key conserved motifs implicit in phenylalanine binding: GAL (amino acid residues 46-48 in human PAH) and IESRP (residues 65-69 in human PAH) (Flydal et al. 2010; Gjetting et al. 2001) . Deletion of the N-terminal regulatory domain of PAH liberates the enzyme of its requirement for activation by phenylalanine, resulting in increased activity of the truncated enzyme (Daubner et al. 1997; Knappskog et al. 1996) . Other factors, for example phosphorylation of the serine at position 16 also aid regulation of PAH (Kappock and Cardonna 1996; Fitzpatrick 1999; Horne et al. 2002; Parniak and Kaufman 1981) . Recent work also indicates that redox signaling involving Cys203 and Cys334 in human PAH may be involved in dynamic regulation of PAH (Fuchs et al. 2012 ).
In some bacteria in which PAH is found, the enzyme is a single-domain, monomeric protein catalyzing the same conversion Leiros et al. 2007 ). In Chromobacterium violaceum, conversion of phenylalanine to tyrosine catalyzed by PAH (cPAH) provides a biosynthetic source of tyrosine, which is also synthesized via p-hydroxyphenyl pyruvate of the chorismate pathway, the same pathway that yields phenylalanine in the organism (Scheme 1) (Herrmann 1995; Singh 1999) . The physiological role of this additional PAHcatalyzed route to tyrosine in bacteria is unclear; under specific conditions, however, for example nutrient starvation, one might expect conversion of phenylalanine to tyrosine to be counterproductive, because this may lead to dangerous depletion of phenylalanine reserves in the organism. Tyrosine supply under such conditions can come exclusively from the chorismate pathway via phydroxyphenyl pyruvate. Therefore, it follows that, similar to its mammalian counterpart, the bacterial enzyme, also, must be regulated. Unlike its mammalian counterpart, however, cPAH lacks a regulatory domain, and a second binding site for phenylalanine has never been observed kinetically or demonstrated structurally (Fitzpatrick 2012) .
Although human PAH (hPAH) is more complex than cPAH and the overall sequence similarity of the proteins is modest (35 %), cPAH contains a region structure similar to that of the catalytic domain of hPAH; both structures can be superimposed with a root mean square deviation (RMSD) of 1.2 Å (Fusetti et al. 1998; Loaiza et al. 2008) . Furthermore, the active sites of both enzymes contain a histidine-histidine-glutamate catalytic triad which, with water, coordinate iron in octahedral geometry. Binding of substrate analogues 3-(2-thienyl)-L-alanine (THA) and L-norleucine in the active site of truncated catalytic domain hPAH has been characterized by use of X-ray crystallography (Andersen et al. 2002 (Andersen et al. , 2003 . Four main contacts seem to secure substrate analogues in place within the second coordination sphere of iron: hydrogen bonding with Ser349 and Arg270, backbone interaction with Thr278, and ring packing with His285 (Andersen et al. 2002) . These amino acid residues are conserved in cPAH, except that threonine has been replaced by leucine. We are not aware of any crystallographic structures of PAH bound to its natural substrate, phenylalanine. Herein, we report our discovery of an additional substrate binding site in cPAH, a site 15.7 Å distal to the active site. ITC data consistent with the presence of this distal site are described. Also, by mutational analysis, we show that binding at the distal may affect catalysis, but not via conformational changes that could be observed by crystal structure analysis.
Experimental
Cloning, expression, and purification of cPAH For crystallization, phenylalanine hydroxylase from Chromobacterium violaceum (cPAH) was sub-cloned from a pET3a vector into a pGEX-6P1 vector by means of standard cloning procedures. The resulting N-terminally fused glutathione S-transferase (GST)-tagged protein was expressed in the E. coli BL21(DE3)pLysS strain (Novagen). Cells were grown at 37°C in Luria-Bertani medium containing 100 lg/ml ampicillin and 50 lg/ml chloramphenicol. When OD 600 reached *0.5, expression of protein was induced with 1 mM isopropyl-b-D-thiogal actopyranoside (IPTG), and proceeded overnight at 18°C with shaking. The cells were centrifuged at 4°C for 10 min at 70009g and the pellet was subsequently resuspended in PBS containing 400 mM KCl and lysed via French Press. The crude extract was centrifuged at 4°C for 1 h at 22,0009g and the pellet was discarded. Further clarification of the supernatant was achieved by use of a final spin of 100,0009g for 15 min at 4°C. Protein was purified on a glutathione-Sepharose column (GE Lifesciences) in accordance with the manufacturer's procedure, using PreScission Protease (GE Lifesciences) to cleave the GST tag. The protein was also purified in buffer containing 50 mM Tris HCl, pH 7.6, 50 mM NaCl, and 1 mM DTT by size-exclusion chromatography on a Superdex S75 column (GE Lifesciences) then anion-exchange chromatography on a HiTrap DEAE Sepharose Fast-Flow column (GE Lifesciences). The purity of the protein was assayed by SDS-PAGE and purified protein was concentrated by use of Amicon Ultra centrifugal filters (Millipore), and buffer exchanged into 50 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), pH 7.4. Protein was stored at -80°C, and concentration was determined spectrophotometrically.
For solution studies, cPAH was also purified from a pET3a vector in the absence of an affinity tag in accordance with a previously published procedure (Volner et al. 2003) with some changes. Briefly, protein expression was induced with 1 mM IPTG and proceeded overnight for 16 h at 18°C. The cells were harvested and lysed via French Press. cPAH was purified by DEAE-cellulose anion-exchange chromatography then gel-filtration chromatography on a Superdex S75 column (GE Lifesciences). Fractions corresponding to cPAH were concentrated, buffer exchanged into 70 mM HEPES, pH 7.4, and stored at -80°C. Protein concentration was determined spectrophotometrically. This sample was also co-crystallized with Phe in the presence of Fe(II) to confirm the distal site binding of the substrate in the presence of native metal (described below).
Generation of cPAH point mutants
All mutant constructs were prepared by use of the QuikChange Site-Directed Mutagenesis kit (Stratagene) and confirmed by DNA sequencing. Mutants were expressed in E. coli and purified by following both purification methods described above. Seeds were generated by first crushing the crystals in solution removed from the reservoir under which the crystals grew, followed by breaking up crystals further by use of Seed Bead (Hampton Research). The total drop size was 5 ll (2 ll protein, 2 ll reservoir solution, 0.4 ll of each additive, 0.2 ll seeding solution). The substrate, phenylalanine, was introduced to the crystals by use of two methods: soaking and co-crystallization. In the soaking experiments, crystals were soaked in a solution containing 1 mM phenylalanine and 25 % ethylene glycol, as cryoprotectant, for 3 h then flash frozen in liquid nitrogen. cPAH (10 mg/ml) was preincubated in solution with 1 mM phenylalanine for 5 h then co-crystallized under the conditions described above. Crystals were soaked briefly in 25 % ethylene glycol and flash frozen in liquid nitrogen. Data from phenylalanine-soaked crystals (1.55 Å ) and co-crystallized phenylalanine-cPAH (1.35 Å ) were collected at beamline 23-ID-D of the advanced photon source at Argonne National Laboratory. Diffraction data were collected at 100 K on a Mar300 CCD detector (Mar USA) and processed by use of HKL3000 software (Otwinowski and Minor 1997) . The crystals belong to the P1 space group with one molecule per asymmetric unit.
To obtain crystals of cPAH in its native Fe(II) metallated state, crystals were grown in a glove box (Innovative Technologies) under a nitrogen atmosphere (B2 ppm O 2 ) in the absence of both nickel and cobalt. The crystallization buffer used in these experiments contained 0.1 M Na-HEPES pH 7.0, 0.01 M magnesium chloride hexahydrate, and 15 % w/v PEG. Crystals were grown by the seeded, sitting drop vapor-diffusion method with 8.3 mM ferrous ammonium sulfate and 8.3 mM guanidine hydrochloride as additives. Phenylalanine soaking was performed as described above, but with a shorter soak period of 20 min, because drops dried out quickly in the anaerobic environment. Crystals were flash frozen inside the glove box after briefly soaking in a solution of 25 % ethylene glycol.
The structure was determined by molecular replacement with the software molrep (Vagin and Teplyakov 1997) of the ccp4 suite (Collaborative Computational Project, Number 4 1994) using the previously published apo-cPAH structure (PDB ID code 1LTU) (Erlandsen et al. 2002) . Cycles of refinement and model building were performed with the software Refmac5 (Murshudov et al. 2011) and Coot (Emsley et al. 2010) , respectively. Anisotropic B factors were used during refinement of all the structures except that of untagged cPAH bound to both Fe(II) and phenylalanine. Weights were optimized during the refinement of two structures: F258A mutant and the structure of untagged cPAH bound to both Fe(II) and phenylalanine. Occasionally, for example refinement of S203P, cPAH phenylalanine-soaked and cocrystallized structures, TLS motion determination (Painter and Merritt 2006) was used. R cryst and R free for the phenylalanine-soaked structure, which includes amino acid residues 7-283 in the polypeptide chain, were 16.3 and 20.7 % respectively. R cryst and R free for the co-crystallized phenylalanine-cPAH structure were 15.9 and 20.7 %. The crystallographic data and refinement statistics are listed in Tables 
Isothermal titration calorimetry
Isothermal titration calorimetry (ITC) experiments were conducted aerobically and anaerobically at 25°C by use of a GE/MicroCal ITC 200 calorimeter. Enzyme solutions were prepared by an overnight dialysis against 50 mM HEPES (pH 7.4). A typical experiment under aerobic conditions consisted of titrating a 1-10 mM phenylalanine solution against 50-100 lM protein solution. To test the selectivity of the distal site, a 1.5 mM solution of tyrosine, a 1.5 mM solution of isoleucine, and a 1 mM solution of alanine were separately titrated against a 50 lM protein solution. A total of 18 injections (2 lL/injection) were performed for cPAH (WT, S203P, T254A, F258A, and Y155A). Reference subtraction (titration of ligand in buffer only) was conducted for each analysis. For each experiment a spacing of 180 s was used between injections. The experiments were performed in duplicate with different titrant concentrations. The data were then analyzed by use of the one-site model in SEDPHAT (v. 10.40) (Houtman et al. 2007 ) and MicroCal Origin software version 7.0 (provided by GE).
In experiments performed to examine active site binding of phenylalanine upon reconstitution of the active site, ITC experiments were conducted in an anaerobic glove box (PlasLabs) under an argon atmosphere at 25°C, to prevent oxidation of (6R)-5,6,7,8-tetrahydrobiopterin dihydrochloride (BH 4 ). Buffer solutions were stored in vials with rubber septa caps and deoxygenated extensively by bubbling argon gas through them. Pre-weighed amounts of solid L-Phe, BH 4 , and ferrous ammonium sulfate were placed in separate vials and placed in the glove box with protein samples and degassed buffers. Ferrous ammonium sulfate was dissolved in 10 mM HCl; both BH 4 and L-Phe were dissolved in dialysis buffer. To reconstitute the apo enzyme with ferrous iron, dissolved oxygen was initially removed from the protein solution by gently pipetting the solution up and down at least 50 times followed by addition of 0.5-1.0 mol ferrous ammonium sulfate (25-50 lM) per mol PAH to the enzyme (50-100 lM). For experiments in which phenylalanine was titrated against reconstituted enzyme, 200 lM BH 4 was also added to the enzyme and the mixture was left to equilibrate at 25°C for 15 min before the start of the experiment. A typical experiment involved titrating either a 1-10 mM solution of phenylalanine or a 0.75-1.0 mM solution of BH 4 against the protein solution.
Steady-state kinetic studies
Enzyme activity was measured on a Shimadzu UV-2501 double-beam spectrophotometer equipped with a thermostat-controlled cuvette holder. Assays were conducted at 20 ± 1°C, by following hydroxylation of phenylalanine to tyrosine at 275 nm. One-milliliter total volume assay mixtures contained 0.8-2 lM cPAH, a fivefold excess of ferrous ammonium sulfate (FeSO 4 ) relative to the enzyme concentration, 0.1 M Na-HEPES (pH 7.4) saturated with O 2 , 100 U/ml bovine catalase, 5 mM dithiothreitol (DTT), and 350 lM 6,7-dimethyltetrahydropterin (DMPH 4 ), and were initiated with 10-1,200 lM L-phenylalanine. Initial rates were determined by measuring absorbance from 10 s up to 20 s after initiation by phenylalanine. Assays for each mutant and the wild-type protein were conducted in triplicate. All kinetic data were analyzed by use of the software Kaleidagraph and fit to the Michaelis-Menten equation 
Molecular dynamics simulations
We performed molecular dynamics simulations using the AMBER package (Case et al. 2012) to elucidate the effect of distal Phe binding on the structure and dynamics of cPAH. We simulated three systems by applying identical simulation procedures: cPAH with bound Fe 3? based on coordinates from Erlandsen et al. (1LTV) and two systems based on the X-ray structure of cPAH with Phe bound to the newly discovered distal site (3TCY). One simulation contained the bound Phe; for the other the ligand was artificially removed. For the last two simulations the bound Co 2? was replaced by a Fe 3? for consistency. For all simulations we removed co-crystallized ethanediol molecules but preserved all resolved water molecules for the simulations. Systems were protonated in MOE (Labute 2009 ) and a truncated octahedral water box with a minimum wall distance of 12 Å was added.
The AMBER force field 99SB-ILDN (Lindorff-Larsen et al. 2010) was used for protein amino acid residues, the TIP3P model for water (Jorgensen et al. 1983 ). The Fe 3? ion was treated as described elsewhere (Fuchs et al. 2012) ; partial charges for free Phe were derived via RESP fitting (Bayly et al. 1993) at the HF/6-31G*-level. Atom types for free Phe were chosen as a combination of N-terminal and C-terminal Phe for the backbone atoms and standard Phe for the side chain. After a detailed equilibration procedure (Wallnoefer et al. 2010 ) 1 ls of sampling trajectories were collected for each of the three systems by the GPU accelerated code of AMBER (Goetz et al. 2012) . Analysis of trajectories included 1D and 2D root-mean-square deviation analysis of protein atom positions to ensure stability of molecular dynamics simulations. Further analysis covered calculation of amino acid residue-wise fluctuations as B-factors and extraction of geometries and secondary structure elements from stored coordinates. 
Results
Crystallographic characterization of substrate binding at the distal site on cPAH
In an attempt to crystallographically characterize substrate binding with cPAH, two methods of ligand introduction were used: crystal soaking and pre-incubation of enzyme and the substrate in solution before crystallization. Crystals of cPAH, soaked in cryoprotectant containing a threefold molar excess of phenylalanine relative to enzyme concentration (in the crystallization drop), diffracted to 1.55 Å resolution (Table 1 ). The cPAH structure used in these experiments was purified as a GST-fused structure after GST affinity chromatography and the tag was proteolytically removed (''Experimental'' section). It was crystallized from a solution that contained both hexamine cobalt(II) chloride and nickel chloride. The structure was determined by molecular replacement (MR) using a previously solved structure of cPAH as the search model (PDB code 1LTU; Erlandsen et al. 2002) . Strong electron density near the active site in the 2Fo-F C map calculated with the model that resulted after the MR search indicated the presence of bound metal, at the same place where iron was seen in a previous structure of cPAH soaked with ferrous ammonium sulfate (PDB code 1LTV; Erlandsen et al. 2002) . We modeled a cobalt(II) ion into this density because we had more cobalt than nickel salt in the crystallization buffer. The structures we discuss hereafter all contain a modeled cobalt ion at the active site, however because the identity of the metal in the active site has not been established, we refer to the structures as metallated PAH. These metallated cPAH models were nearly identical with the Fe(III)-bound cPAH structure reported elsewhere (Erlandsen et al. 2002) and our own structure of cPAH purified by following the procedure described by Erlandsen et al. and crystallized in a glove box in an oxygen-free environment in the presence of Fe(II) (discussed below). Refinement of the crystallographic data led to final R crys and R free values of 16.3 and 20.7 %, respectively (Table 1) . Clear electron density for phenylalanine was observed, indicating phenylalanine was bound to the enzyme, but not in the active site. A 2F o -F c electron density difference map, contoured at r = 2, depicted density that was unambiguously interpreted as phenylalanine in a site 15.7 Å distal to the active site ( Fig. 1) (distance between Cf atom of the substrate and the active-site metal). Phenylalanine (final concentration 1 mM) was preincubated in solution with cPAH for 5 h before crystallization without additional phenylalanine soaking after crystallization. These crystals diffracted to a resolution of 1.35 Å and the structure was refined to R crys and R free values of 15.9 and 20.7 %, respectively (Table 1) . Electron density shows that, once again, phenylalanine is nestled in the distal binding site, occupying the same orientation as seen in the soaked crystals, with no discernible density in the active site. The average B-factors estimated after final refinement for phenylalanine from soaked and co-crystals are 17.6 and 18.7 Å 2 , respectively. In comparison, average B-factors for the entire phenylalanine-soaked and co-crystallized protein are 16.1 and 13.6 Å 2 , respectively (Table 1) , suggesting nearly complete occupancy at the distal site.
Structural changes to the backbone on binding of phenylalanine in the distal site are minimal, with a rootmean-square deviation (RMSD) of 0.33 Å among alpha carbons, and predominately localized to amino acid residues that constitute the binding pocket (Fig. 2a) . The 254-257 loop, which connects the a13 helix with the a14 helix, shifts slightly outward. Most notably, Thr254 is displaced approximately 3.2 Å and rotates to create enough space to accommodate binding of phenylalanine (Fig. 2b) . The binding pocket, comprising mainly hydrophobic amino acids and phenylalanine, is stabilized largely by van der Waals contacts with hydrophobic side chains lining the pocket (Fig. 3a) . For example, the aromatic ring of phenylalanine stacks against that of Phe258 at an average interplanar distance of 3.8 Å . Additional van der Waals contacts are made with phenylalanine and the side chains of Leu178, Tyr155, Tyr159, and Ala158. Hydrogen bonding also seems to be important in this binding and occurs between phenylalanine and the main chain atoms of Pro256, Phe258, Asp257, Thr254, and Ala158 (Fig. 3b) . Phenylalanine is further stabilized by hydrogen bonding with an invariant water molecule that interacts with Gly162 and Tyr262. All these interactions seem to ensure tight binding of the substrate at this distal site, with nearly each atom of the substrate making contact with one or more atoms on the amino acid residues lining up the distal site pocket, indicative of a high-affinity interaction. Finally, the distal binding pocket seems to be closed after substrate binding by formation of a salt bridge near the surface between Asp257 and Lys165 (Fig. 3b) . These results indicate that the distal site has substantial attractive forces for binding of the substrate. We were curious about whether this second phenylalanine site is conserved in other bacteria yielding single domain, monomeric PAH. Alignment of other bacterial sequences to C. violaceum indicate that many of the amino acid residues are conserved in some bacterial PAHs whereas such conservation is not observed for others, suggesting some proteins may have the site and others do not (Supporting Fig. S1 ). The absence of any discernible electron density for phenylalanine at the active site could mean that it was occluded in some way or that binding here requires the presence of the pterin cofactor (discussed below). Preincubation of phenylalanine with the enzyme before crystallization should discount the notion that the lack of density for phenylalanine at the active site is the result of crystal packing. Furthermore, inspection of crystal packing indicates that, as expected for a polar active site, solvent channels are not impeded by packing.
As mentioned above, the studies presented so far were conducted with protein purified by GST affinity chromatography and the GST tag was removed proteolytically (''Experimental'' section). However, we noticed that the catalytic activity of the protein purified in this manner was lower than that of the protein purified without any tag reported elsewhere (Volner et al. 2003 ) (''Experimental'' section and Supporting Fig. S2 ). The GST method did not include EDTA in the buffer, but the later procedure did). We therefore chose to conduct further studies with untagged protein, purified by use of a procedure reported elsewhere, for kinetic analysis and ITC (discussed below). We confirmed by X-ray structure analysis that the untagged protein binds to phenylalanine at the distal site (Supporting Fig. S3 ).
To offset concern that phenylalanine may bind in the distal site as the result of occupancy of the active site by an inhibitory metal, for example cobalt (Zoidakis et al. 2005) , the untagged protein purified by the procedure of Erlandsen et al. (2002) was crystallized in the presence of the native metal, iron, in a glove box under nitrogen atmosphere. These crystals diffracted at a resolution of 2.14 Å and the structure was refined to R crys and R free values of 20.6 and 25.1 % respectively (Table 1) . Electron density indicates that with Fe(II) bound in the active site, phenylalanine still preferentially binds in the distal site in the same orientation as described above (Supporting Fig. S4 ). From this structure it can be concluded that phenylalanine binding in the distal site does not arise only when an inhibitory metal occupies the active site, but also when the enzyme is bound to its native metal. Fig. 2 Global structural changes in the backbone of cPAH on binding of phenylalanine in the distal site are minimal. a Superimposition of five cPAH structures: wt-phe bound (pink), wt-Co(II) (cyan), wt-apo (1LTU, magenta), wtFe(III) (1LTV, blue), and wtFe(III)-BH 2 (1LTZ, green) indicates the backbone is relatively unchanged after phenylalanine binding. b The most notable structural change occurs when T254 shifts to create a space to accommodate phenylalanine binding Distal site phenylalanine binding in solution ITC was used to elucidate whether binding in the distal site also occurs in solution. In contrast with our expectation that two separate binding events, one corresponding to the active site and one to the distal site, would be observed, titration produced a binding isotherm (Fig. 4a ) that could be satisfactorily fitted to a one-site model yielding a dissociation constant (K d ) of 24 ± 1.1 lM (Table 3) . Such a result may indicate the presence of only one binding site on the protein or two sites with similar K d and enthalpy of binding (Mayers et al. 2011) . To investigate this further, distal and active-site mutants were generated. Three-point mutations (F258A, Y155A, T254A) in the distal site were introduced in side chains that interact with bound phenylalanine, presumably resulting in an enzyme with reduced affinity for phenylalanine at the distal site. Phe258 was selected because it participates in a stacking interaction with the aromatic ring of phenylalanine. Tyr155 also makes contact with phenylalanine in the distal site, and the side chain of Thr254 moves to make space for phenylalanine binding. The results of the ITC experiments indicated a marked decrease in the affinity for phenylalanine by the three mutants: T254A, Y155A, and F258A with K d s of 376 ± 10, 559 ± 30, and 775 ± 44 lM, respectively (Figs. 4b-d; Table 3 ). Further analysis using a two-site model did not reveal any statistical difference from the one-site model. The precision of the stoichiometry (n) becomes ambiguous for the mutants because the c value (the ratio of total ligand concentration in the cell to the K d value) is small (c \ 40) because of the large K d and the shape of the thermogram (Broecker et al. 2011) . The clear impairment of phenylalanine binding in all three cases indicates that the binding characterized in the wild-type cPAH ITC experiment involved either the distal site alone or at least a contribution of the distal site to binding in solution.
To eliminate the possibility that the mutations in the distal phenylalanine binding site may have impaired binding in the active site as a result of gross changes in the global structure of the proteins, we crystallized both Y155A and F258A mutants (purified using GST affinity chromatography). The crystal structures for both mutants were found to be nearly identical with that of wild-type cPAH in the active site region of the proteins (Fig. 5 , Table 2 ). For Y155A, the only difference from the wild type is localized near the distal site. The gap generated by removal of the bulky tyrosine phenolic group was occupied Fig. 3 by a nearby aromatic residue, Tyr 159, which flips its ring to fill the cavity (Supporting Fig. S5 ). This structural adjustment is indicative of some conformational plasticity in the distal site, perhaps in the entire protein. The Y155A mutant crystals were soaked with phenylalanine (at the same concentration as wild type) and, consistent with the To further investigate binding in solution, a mutant at the active site, S203P, expected to lead to reduced binding of phenylalanine there, was studied. The choice of this mutation is based on the fact that a naturally occurring mutation of the equivalent serine residue in hPAH leads to PKU, possibly because of loss of hydrogen bonding with the substrate at the active site, resulting in a catalytically impaired enzyme. This is supported by the crystal structure of the catalytic domain of hPAH bound to THA, which shows that the serine residue is engaged in hydrogen bonding with the substrate analog at the active site (Andersen et al. 2002) . Indeed, our results show that this mutant is catalytically less active than wild-type cPAH ( Fig. 8a ; Table 5 ). Interestingly, S203P cPAH has better binding affinity for phenylalanine than wild-type, with K d close to 7 ± 0.3 lM ( Fig. 4e; Table 3 ). It is unclear why S203P has greater affinity for phenylalanine than wild type cPAH. It is possible that the binding affinity probed by ITC is actually an average of two distinct binding events, one at the distal site (K d1 ) and one at the active site (K d2 ), with K d1 \ K d2 , which seems reasonable for the following reason. Our crystal structures obtained in the presence of phenylalanine indicate occupancy the distal site, but not the active site, by phenylalanine, even in the absence of steric occlusion. Therefore, it is conceivable that by impairing the contribution of the presumed higher-affinity site, the distal site (represented above as K d1 ), the overall affinity for substrate will be reduced, resulting in higher K d values Fig. 5 The distal mutant crystallographic structures were found to be nearly identical with those of wild-type cPAH. Superimposition of Y155A (red) and F258A (gray) on the wild-type cPAH phenylalaninebound structure (pink) revealed no changes to the structure in the backbone a or in the active site b Eur Biophys J (2013) 42:691-708 701 (Table 3 , F258A, T254A, Y155A). Furthermore, impairment of the lower affinity site, the active site (represented above as K d2 ), would have the opposite effect: overall binding would be improved, resulting in lower K d values, as seen with the S203P mutant. Alternatively, the S203P mutation may actually lead to better but unproductive binding of Phe at the active site (catalysis by this mutant is impaired) because of attraction of the greasy pyrrolidine ring of proline. Such unproductive binding may reflect a gain in overall affinity for phenylalanine. It is also possible that mutation of Ser203 might have caused conformational rearrangement at the distal site, leading to better binding there; no noticeable change in the crystal structure of either the active or distal site of the S203P mutant is observed, however, with distal-site binding occurring in the mutant, as expected from the co-crystal structure (Table 2 ; Supporting Fig. S6 ). Thus our ITC data and crystal structures so far seem to provide evidence of phenylalanine binding in the distal site but no evidence of it binding in the active site. One explanation for why we cannot detect active site binding of phenylalanine by ITC, even though we know it does exist because the enzyme catalyzes conversion of phenylalanine to tyrosine, could be that the affinity for phenylalanine in the active site of cPAH depends on the presence of cofactor, pterin. This notion is based on the kinetic analysis of Volner et al. (2003) which showed that binding of BH 4 precedes phenylalanine and hence may be required for its binding. We therefore reasoned that reconstitution of the active site by including Fe(II) and BH 4 may enhance its binding affinity for the substrate in that site. BH 4 was used instead of DMPH 4 , which is used in kinetics (discussed below), because it binds better in ITC (kinetically, the two are almost the same) (Volner et al. 2003; Citron et al. 1992; Phillips et al. 1984) . These experiments were conducted under an anaerobic argon atmosphere to prevent oxidation of BH 4 and Fe(II). The K d values obtained are presented in Table 4 . Contrary to our expectation, we did not notice a significant difference in phenylalanine binding with wildtype cPAH or any substantial difference for the mutants S203P, T254A, and F258A (Fig. 6a-d) . Substantially improved binding in the presence of BH 4 and Fe(II) was, however, observed for Y155A (Fig. 6e) . Overall, these results indicate that ITC is more sensitive to distal than to active site binding and that pterin's presence in the active site has no bearing on phenylalanine binding. In fact, going back to the structure of hPAH bound to BH 4 and THA (Andersen et al. 2002) , we could see no contact between BH 4 and the substrate analog, indicating that our assumption that pterin binding will improve affinity for phenylalanine is perhaps not valid. Accordingly, none of the variants we studied, including S203P, resulted in any improvement in binding affinity for phenylalanine in the presence of pterin. It is possible that reconstitution is partial at best, owing to binding of BH 4 being inadequate under the conditions used here, although we did observe BH 4 binding with the protein samples in separate titration experiments with 16-44 lM affinity for wild-type and mutants (Table 4 ; Supporting Fig. S7 ). Based on this, we expected the cofactor to be bound under the conditions used in reconstitution.
A noticeable improvement in K d was observed for Y155A when both BH 4 and Fe(II) were present. This can be explained by the advent of a new mode of binding which is different than productive binding at the active site. If it was active site productive binding, Y155A would be a better catalyst than T254A, but it is not. Also, the kinetic data show that this mutant behaves anomalously, with less activity at higher concentration of substrate, indicative of unproductive binding at high substrate concentration (Fig. 8a) . It is unlikely that BH 4 and/or Fe(II) binding may have bolstered the distal site slightly, leading to improvement there, although this cannot be ruled out.
The distal site selectively binds phenylalanine It is possible that the distal binding site observed here is a result of accidental binding of the substrate at a sticky patch on the surface. Such a patch is expected to be less selective; it could bind other amino acids also. To ascertain whether the distal site binds phenylalanine selectively, attempts were made to obtain binding information for two other amino acids, tyrosine and alanine, both crystallographically and by calorimetry. We were most interested in the possibility of tyrosine binding, because, if bound in the distal site, it could serve to regulate the enzyme by product inhibition. We also chose to use isoleucine as a hydrophobic mimic of phenylalanine and alanine as a general representative of most amino acids. Co-crystallization and crystal soaking with both tyrosine and a tyrosine analogue, N-acetyl-L-tyrosine (Sigma), failed to yield any detectable electron density for tyrosine in the distal site. Furthermore, titration of tyrosine, isoleucine, and alanine against cPAH by ITC did not reveal any binding (Supporting Fig. S8 ). These results indicate the distal site binds phenylalanine with some selectivity.
Catalytic properties of the distal and active site mutants
To determine the role of the distal phenylalanine binding site in cPAH, kinetic analysis of the distal site mutants was performed under steady-state conditions. The enzymatic activity of cPAH and its mutants was investigated by holding oxygen and DMPH 4 at saturation while varying the concentration of phenylalanine. The kinetic results for the distal site mutants and for wild-type cPAH are summarized in Table 5 . T254A, with binding reduced by approximately a factor of 15 according to ITC, has catalytic activity somewhat similar to that of the wild type, although the fact that it is somewhat less active than the wild type is clearly discernible at low substrate concentrations. Loss of catalytic efficiency for the two other mutants, Y155A and F258A, was much greater than for the wild-type enzyme. The effect of the distal site mutation on the second-order rate constants k cat /K M shows that the mutants are noticeably less effective catalysts than the wild type protein (Table 5 ). The k cat /K M values reported in Table 5 Table 3 ). This trend was reproduced in three different measurements (the errors are shown in Fig. 7a, b) . However, because of the modest trend observed in the distal mutants, it is unclear from the kinetic data alone if the distal site has any regulatory role on catalytic turnover. Perhaps we must depart from steadystate kinetics to answer this question. We observed no noticeable changes in the position of residues within the active site region in the crystal structures of the distal mutants Y155A and F258A. It is possible that the mutations may have altered the dynamic properties of the active site in solution, leading to altered catalysis, effects that cannot be seen in the X-ray structures, which represent snapshots of the thermodynamically most stable form of the proteins.
Dynamic effects of distal site binding probed by molecular dynamics simulations
To test whether the distal and active site are linked dynamically, molecular dynamic simulations were performed on a 1 ls time scale (''Experimental'' section). Our results do not establish a dynamic link between the two sites, because no significant changes in active site structure and dynamics were observed upon Phe binding. However, comparison of B-factors from the three models under study clearly reveals that the phenylalanine-bound complex is significantly more rigid than the two phenylalanine-free models (Figs. 8a, b) . Furthermore, we observe a second conformational state for residues around the distal Phe binding site. Whereas extension of the native a helix to a 3 10 helix for residues 247-249 is not observed in the simulation of cPAH with bound Phe, we see this transition for both simulations with vacant remote site several times over the simulation time of 1 ls (occupancy 3 10 helix 22 and 44 % respectively). On the basis of these observations, it is plausible that phenylalanine binding in the distal site is important for stabilizing cPAH in catalytically competent states by limiting dynamic excursions into unproductive states (''Discussion'' section, below).
Discussion
Most enzymes have evolved to have their active sites adorned with residues for optimum substrate binding.
Having an additional site usually serves to regulate the enzyme, most commonly seen in multimeric allosteric enzymes. Although the exact function of cPAH in Chromobacterium violaceum is not known, the fact that it catalyzes the conversion of phenylalanine to tyrosine, two vital primary metabolites, and that conversion of phenylalanine to tyrosine is essentially irreversible, implies this enzyme, similar to its mammalian counterparts, should be regulated. It is conceivable that when concentrations of phenylalanine are low, conditions that may arise when the free-living organism is exposed to nutrient starvation, it would be counterproductive to have the cPAH route to tyrosine continue, because this may deplete the phenylalanine pool in the organism. When the concentration of phenylalanine increases, the distal site effect would ''activate'' the enzyme (see below) producing a feed-forward effect, known in the mammalian systems. In the light of a recent publication which indicates that phenylalanine can form ordered amyloid fibrils (Adler-Abramovich et al. 2012), another possible function of cPAH could be to prevent fibril formation in the organism by converting phenylalanine to tyrosine. Perhaps binding in the distal site could activate the protein in these circumstances. The genome of Chromobacterium violaceum has been sequenced (Vasconcelos et al. 2003) . As is generally true of other free-living organisms, a striking characteristic of this organism is that it can thrive under dramatically fluctuating environmental conditions. Consistent with this behavior, a significant portion of its genome is dedicated to open reading frames that can appropriately respond to change in such conditions as nutrient starvation (Vasconcelos et al. 2003) . It is tempting to speculate that having a separate binding site for the substrate in an enzyme involved in amino acid metabolism could confer some advantages enabling the organism to reprogram its biosynthetic machinery. Because it has been established that hPAH is subject to allosteric activation by its effector, phenylalanine, it is natural to question whether the distal binding pocket of cPAH is also a site for allosteric regulation. Although it is not implausible to find allosteric sites in single-domain proteins (Hardy and Wells 2004) ; the distal binding site we have uncovered does not really qualify as an allosteric site in the conventional sense, because we do not observe conformational coupling between this and the active site. Superimposition shows that the apo and phenylalaninebound structures have nearly identical positions of side chains that connect the two sites, indicating lack of conformational cross talk between the two (Fig. 3c) . However, we cannot discount the idea that allostery can occur without conformational changes in the backbone, and that it may, instead, arise from changes in dynamics (Cooper and Dryden 1984; Tsai and Nussinov 2008; Tzeng and Kalodimos 2011) . It is possible that cPAH in solution passes through an ensemble of distinct conformations, some of which are productive and some not. Binding of phenylalanine at the distal site may limit the ensemble in such a way that, on average, the enzyme spends more time with its active site in the productive form. This is one of the ways the distal site may contribute to catalysis by positive regulation. The observation of neighboring side chains readjusting in the Y155A mutant is consistent with the dynamic nature of the enzyme. Our MD simulation analysis, although not showing any conformational coupling between the distal site and the active site, does provide some evidence of rigidification on substrate binding at the distal site, on the basis of which we propose distal Phe binding as a potential mechanism locking cPAH in a catalytic active conformation.
The distal site may also serve to negatively regulate the enzyme under conditions of low substrate concentration. Under limiting substrate conditions, one would expect the rate of an enzyme-catalyzed reaction to be reduced if a second binding site exists, by a factor corresponding to the fractional occupancy at the two sites. We do not know the relative affinity of the distal site for phenylalanine compared with that of the active site. Therefore, the extent to which the rate would be reduced cannot be estimated. Nevertheless, the fact that there is another site for substrate binding would, in effect, cause apparent inhibition of the Fig. 7 a Initial velocity divided by total enzyme concentration as a function of substrate concentration from three independent experiments for wild type cPAH and three distal site mutants, Y155A, T254A, and F258A provides evidence that mutation in the distal site leads to a noticeable loss in catalytic activity at each concentration of substrate examined. Also shown in the plot is initial velocity as a function of substrate concentration for the active site mutant studied, S203P, for which loss of catalytic activity was greatest for all the mutants under investigation. b A plot of initial velocity vs. phenylalanine concentration from Y155A shows sigmoidal dependence of rate on substrate concentration Eur Biophys J (2013) 42: 691-708 705 enzyme under conditions in which the concentration of phenylalanine is low in solution: a condition that would arise when the free-living bacterium is exposed to nutrient starvation. This type of inhibition would prevent conversion of phenylalanine to tyrosine, thereby preventing depletion of phenylalanine reserves in the organism under such conditions. Recently, the crystal structure of another bacterial PAH, a single-domain monomeric protein similar to cPAH, has been reported. The crystal structure of this PAH is similar to that of cPAH, but kinetic study of the enzyme seemed to reveal sigmoidal dependence of rate on substrate concentration (Leiros et al. 2007 ), a characteristic of multimeric allosteric enzymes. For this reason the authors suspected the presence of a ''long-lived dead-end complex of the substrate with the enzyme (Leiros et al. 2007 )''. It is tempting to link that observation with the crystallographic observation we are reporting. Such behavior may be explained by invoking a second binding mode, presumably at a second binding site distinct from the active site. We noticed discernible sigmoidal character of the velocity vs. substrate concentration plot for Y155A (Fig. 8b) . It is, however, unclear why we do not observe sigmoidal kinetics plots for the other mutants studied, or for wild type cPAH. It is possible that our experimental conditions preclude us from observing any type of cooperativity existing in these systems.
Although more work is necessary to establish a link between the distal site and enzyme regulation, we believe the results presented here are important for several reasons. First, our study is the first to characterize binding of the natural substrate phenylalanine to any PAH. Second, it reveals the unexpected presence of another substrate binding site in a single-domain enzyme. The relevance of this work may be more far-reaching than PAH itself. Such enzymes as PAH, which are involved in primary metabolism, must be regulated, both in mammalian or bacterial organisms. However, the bacterial genome tends to be simple, with many of their enzymes lacking sophistication in terms of having extra domains for regulatory binding effects; yet, they have the same need for regulation. If more and more metabolic enzymes from bacterial sources are crystallographically characterized bound to their natural substrate, we may be able to determine how common is the presence of such additional binding sites. 
